Experimental HER2 drug trial halted early – what we know
NCT ID NCT05013554
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 29 times
Summary
This early-stage trial tested a new drug called SAR443216 in 44 adults with advanced HER2-positive cancers (like breast, lung, or stomach cancer) that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was terminated early, so results are limited, but it aimed to see if the drug could shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 0560002
Ghent, 9000, Belgium
-
Investigational Site Number : 1580001
Taichung, 404, Taiwan
-
Investigational Site Number : 1580002
Tainan, 704, Taiwan
-
Investigational Site Number : 2500001
Pierre-Bénite, 69495, France
-
Investigational Site Number : 2500002
Villejuif, 94800, France
-
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, 05505, South Korea
-
Investigational Site Number : 7240001
Madrid, Madrid, Comunidad de, 28040, Spain
-
Investigational Site Number : 7240002
Madrid / Madrid, Madrid, Comunidad de, 28050, Spain
-
Investigational Site Number : 7240003
Barcelona, Barcelona [Barcelona], 08035, Spain
-
~University of Texas - MD Anderson Cancer Center Site Number : 8400002
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.